Oral COTI-2 Is Effective As A Single Agent And In Combination With Gemcitabine In An Animal Model Of Human Pancreatic Cancer

Critical Outcome Technologies Inc. (COTI) (TSX VENTURE: COT) announced positive results today from animal experiments carried out at a prominent Canadian cancer research facility. This new series of experiments adds to the already impressive data package for COTI-2, demonstrating efficacy as a single agent and in combination with first line therapies with low toxicity in seven different animal models of human cancers.